Infectious Disease Market Projected to Grow by 5.7% Led by Pfizer, Gilead Sciences, and GSK

According to a report by GlobalData, the infectious disease market is projected to grow actively from 2023 to 2029 and sales are predicted to reach $150 billion by 2029. It is expected that Pfizer, Gilead Sciences, and GlaxoSmithKline (GSK) will be the major players in the market.

What You Need to Know: 

• The infectious disease market is forecasted to grow at a rate of 5.7% annually between 2023 and 2029, despite a 63.8% decrease in COVID-19 vaccine sales in 2022.
• Pfizer, Gilead Sciences, and GSK are expected to dominate the market, collectively generating 62% of total infectious disease drug sales in the stated period.
• High sales of COVID-19 therapeutics and increased demand for HIV drugs partly offset the decline in vaccine sales.
• Pfizer is expected to stay the market leader despite a predicted 9.2% decline in sales from 2023-2029 due to the robust performance of its COVID-19 products, Comirnaty and Paxlovid.
• Gilead’s sales growth from 2023-2029 is forecasted to be 12.4%, driven by its HIV drug, Biktarvy.
• GSK is set to see growth from its shingles vaccine, Shingrix, and HIV drug, Dovato.

To read more, click here.